Calcium Carbonate versus Calcium Acetate as Phosphate binder

Phosphate binder
Ph D: Neven Mohamed
For many years, calcium-containing phosphate binders (calcium acetate and calcium carbonate) were considered the best choice in the treatment of hyperphosphatemia, due to they are effective, possessed only moderate side-effects and suppressed parathormone levels with the intention of counteracting progression of secondary hyperparathyroidism. In two head-to-head observational studies (CARE, ARNOS), calcium-containing binders showed signals of clinical superiority versus the comparator sevelamer-HCl.[1.2] 

Nevertheless, calcium may be absorbed significantly, which may result in a positive calcium balance and actively contribute progressive cardiovascular and soft-tissue calcification in patients at risk.[3]

Calcium acetate has similar effect on serum phosphate levels as compared to calcium carbonate in patients on maintenance haemodialysis. However, calcium acetate results in lesser frequency of hypercalcaemia as compared to calcium carbonate. Tolerance to both drugs was similar, though patients complained of more muscle cramps while taking calcium acetate.
Calcium Salt
Calcium Content
calcium acetate
253 mg (12.7 mEq) per g (20% elemental calcium) 
calcium carbonate
400 mg (20 mEq) per g (40% elemental calcium) 

Hyperphosphatemia in Chronic Renal Failure
Oral
Recommended initial dose of calcium acetate is 1.334 g (338 mg of calcium) three times daily with meal; gradual increase in dose according to serum phosphate concentrations, prevents occurring  of hypercalcemia.
Manufacturer states that most patients require about 2–2.67 g (about 500–680 mg of calcium) with each meal4. However, some experts recommend limiting dosage of calcium provided by phosphate binders to ≤1.5 g daily and limiting total calcium intake (including dietary calcium) to ≤2 g daily; dialysis patients who remain hyperphosphatemic despite such therapy should receive a calcium-containing phosphate binder in combination with a non-calcium-, non-aluminum-, non-magnesium-containing phosphate binder.5

References:
1.      Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65:1914–1926.
2.      Jean G, Lataillade D, Genet L, et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 2011; 15:485–492.
3.      Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478–1483.
4.      Braintree Laboratories. PhosLo (calcium acetate) tablets prescribing information (dated May 1992). In: Physicians’ desk reference. 52nd ed. Montvale, NJ; 1998:733-4.
5-National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 5. Use of phosphate binders in CKD. 2003. Available at . Accessed 2005 Mar 22

Comments

Post a Comment

Popular posts from this blog

Pharmacy Examining Board of Canada Questions & Answers

Image
Overview Q1 What is the Pharmacy Examining Board of Canada? The Pharmacy Examining Board of Canada ( PEBC ) is the national certification body for the pharmacy profession in Canada. PEBC is a non-profit organization with more than 40 years of experience in assessing the qualifications and competence of candidates for licensing by pharmacy provincial regulatory authorities. Established by Special Act of Parliament on December 21,1963, PEBC functions as an arms-length national examining board for pharmacists seeking entry-to-practice licensure in Canada. Q2 What is the purpose of the PEBC?
Read more

Paints in pharmacy| glycerin borax preparation is the first

Image
(1) GLYCERIN BORAX PREPARATION 13% Borax 13gm Glycerin to 100ml Levigate the borax powder into a suitable amount of glycerin then complete to 100ml.  Glycerin of borax uses: Used as a soothing agent in mouth ulcers also used in nipple fissures. (2) GLYCERIN TANNIC ACID PAINT 15% Tannic acid 15gm Glycerin to 100 ml Astringent in spongy gum and sore throat and applied to eyelid in trachoma. 1g of Na-citrate can be added (3) Glycerin borax and Tr.benzoin SOLUTION Glycerin borax 20 ml Tr.benzoin 10 ml Used in nipple fissure (4) DENTAL GLYCERIN ( zinc chloride) ZnCL2 1gm Glycerin 1.6ml H2O 0.5ml Alcohol 1.5ml used for de-sensation for exposed dentin (5) GENTIAN VIOLET PAINT (Rosaniline dyes) Gentian violet 1 gm Alcohol 70% 100 ml Used as antiseptic and in moniliasis. 2g of G. V can be used with 100 ml of glycerin borax in breast fissures. (6) ALCOHOLIC MERCUROCHROME PAINT Mercurochrome 2gm Alcohol 70% to 100 ml (7) Mercurochrome
Read more

Facts about SOVALDI Therapy

Image
SOVALDI  It is a nucleotide analog polymerase inhibitor, that use in patients with chronic hepatitis C, in combination with ribavirin or interferon plus ribavirin, and the cure rate in clinical trials reached 95%. Here is some facts about SOVALDI that pharmacist must know: Active constituent of SOVALDI is sofosbuvir 400 mg. SOVALDI is effective against the four genotypes of HIV infection, including patients with HCC that in waiting list for liver transplantation, and those carrying HIV-1/HCV co-infection. SOVALDI not recommended using alone for Chronic Hepatitis C patients. The dose of SOVALDI is 400 mg once daily, to be taken regardless of food. Genotype-1 HCV treated for 12 weeks with SOVALDI +Peginterferon alfa +ribavirin, and for 24 weeks if used without peginterferon alfa. Genotype-2 HCV treated for 12 weeks with SOVALDI +ribavirin. Genotype-3 HCV treated for 24 weeks with SOVALDI +ribavirin. Genotype-4 treated for 12 weeks with SOVALDI +Peginterferon alfa
Read more